Mumbai, India; May 13, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and “Cipla”), it announced today that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the production and distribution of the experimental drug Remdesivir, which has been granted an Emergency Use Permit (EUA) issued by the U.S. Food and Drug Administration (FDA) for the treatment of patients with COVID-19. This agreement is part of Cipla`s efforts to improve global access to health care for patients affected by the pandemic. The company`s recent agreement aims to increase access to life-saving therapies and diagnostic infrastructure around the world for people in distress. Founded in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generic drugs and portfolio deepening in our local markets, India, South Africa, North America, as well as key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and safety system segments are known. Our 46 production sites worldwide produce more than 50 pharmaceutical forms and more than 1,500 products with state-of-the-art technology platforms to serve our more than 80 markets. Cipla is third in the pharmaceutical industry in India (IQVIA MAT Mar`20), the third largest private pharmaceutical market in South Africa (IQVIA MAT Mar`20) and is one of the most widely used generic companies in the United States.
For more than eight decades, patient action has inspired every aspect of Cipla`s work. In 2001, the provision of three paradigm-changing antiretroviral treatments for HIV/AIDS, at less than $1 a day in Africa in 2001, is widely recognized as having contributed to placing inclusion, accessibility and affordability at the heart of the HIV movement. As a responsible corporate citizen, Ciplas makes the humanitarian approach to public health its goal of “care of life” and deep-rooted community ties wherever it exists, a partner of choice for global health authorities, peers and all stakeholders. For more information, please visit www.cipla.com or click on Twitter, Facebook, LinkedIn. As part of the agreement, Cipla will be authorized to manufacture API and finished products and market them in 127 countries, including India and South Africa, under Cipla`s own brand name. Cipla obtains the know-how of Gilead Sciences, Inc. to produce the API and finished product on a commercial scale. Cipla`s significant geographic and commercial presence will help make this therapy accessible to more patients and more markets. The agreements allow distribution in the following countries: The Indian pharmaceutical company Cipla has signed a licensing agreement with Multi G in Belgium for the distribution of its Covid-19 Covi-G fast antibody analysis kit in Europe and other emerging markets.